{"entity":{"id":"nct06844422","kind":"trial","name":"Adapted Guided Stereotactic Body Radiotherapy Combined With Chemotherapy and Enhancement of Novel Drug Ivonescimab for Pancreatic Cancer (ASCEND)","aka":[],"tldr":"A phase 1/2 trial of ivonescimab in pancreatic cancer, run by Shandong Cancer Hospital and Institute, now recruiting.","summary":"Adapted Guided Stereotactic Body Radiotherapy Combined With Chemotherapy and Enhancement of Novel Drug Ivonescimab for Pancreatic Cancer (ASCEND) is a phase 1/2, interventional study registered as NCT06844422 by Shandong Cancer Hospital and Institute, with a registry enrolment figure of 37 participants, started 2025-02-08 and due to reach its primary completion in 2028-02-18. Interventions recorded: Ivonescimab. Conditions listed: Pancreatic Cancer. Primary outcome: Maximum Tolerated Dose (MTD); Dose-Limiting Toxicity (DLT); Recommended Phase 2 Dose (RP2D). Pancreatic eligibility wording from the registry: \"At least one measurable pancreatic cancer lesion, as defined by Response Evaluation Criteria in Solid Tumors (RECIST) 1\". Sites: China. No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-09-24","links":[{"label":"ClinicalTrials.gov NCT06844422","url":"https://clinicaltrials.gov/study/NCT06844422"}],"tags":["ctgov-ingest","pancreatic-deep-dive"],"related":[],"cancers":["pancreatic"],"sections":[],"technologies":["checkpoint-inhibitor","sbrt"],"targets":[],"drugs":["ivonescimab"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT06844422","phase":"1/2","setting":"Adapted Guided Stereotactic Body Radiotherapy Combined With Chemotherapy and Enhancement of Novel Drug Ivonescimab for Pancreatic Cancer (ASCEND) -A Single-Arm Phase Ib/II Trial","sponsor":"Shandong Cancer Hospital and Institute","enrolled":37,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct06844422/","neighbours":{"cancer":[{"id":"pancreatic","kind":"cancer","name":"Pancreatic ductal adenocarcinoma","route":"/cancers/pancreatic/"}],"technology":[{"id":"checkpoint-inhibitor","kind":"technology","name":"Immune checkpoint inhibitors","route":"/technologies/checkpoint-inhibitor/"},{"id":"sbrt","kind":"technology","name":"SBRT / SABR (stereotactic radiotherapy)","route":"/technologies/sbrt/"}],"drug":[{"id":"ivonescimab","kind":"drug","name":"Ivonescimab","route":"/drugs/ivonescimab/"}],"term":[{"id":"pancreatic-trials-open-today","kind":"term","name":"Pancreatic cancer trials open today (registry snapshot and UK sites)","route":"/terms/pancreatic-trials-open-today/"}]}}